SCHEMBL7708229

SCHEMBL7708229

CC1Oc2ccc(C(Cc3ccc([N+](=O)[O-])cc3)NC(=O)OC(C)(C)C)cc2NC1=O.CC1Oc2ccc(C(N)(Cc3ccc(S(N)(=O)=O)cc3)C(=O)OC(C)(C)C)cc2NC1=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 7/20 0.35
PPARG P37231 1/20 0.31
PPARA Q07869 1/20 0.31
CA1 P00915 1/20 0.31
CA4 P22748 1/20 0.31
CA7 P43166 1/20 0.31
CA9 Q16790 1/20 0.31
PARP1 P09874 1/20 0.30
ALDH1A1 P00352 1/20 0.30
LMNA P02545 1/20 0.30
TP53 P04637 1/20 0.30
MAPT P10636 1/20 0.30
PKM P14618 1/20 0.30
HPGD P15428 1/20 0.30
TSHR P16473 1/20 0.30
AGTR1 P30556 1/20 0.30
HTT P42858 1/20 0.30
RAB9A P51151 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7708231 0.92 CA2 (0.39) CA2PPARGPPARACA1CA4
SCHEMBL7708221 0.80 PARP1 (0.40) PARP1ALDH1A1LMNATP53MAPT
SCHEMBL7713283 0.78 PARP1 (0.40) PARP1ALDH1A1LMNATP53MAPT
SCHEMBL7710783 0.78 PPARG (0.39) PPARGPPARAALDH1A1LMNATP53
SCHEMBL7095139 0.78 CA2 (0.41) CA2CA1CA4CA7CA9
SCHEMBL7713294 0.76 PARP1 (0.42) PARP1ALDH1A1LMNATP53PKM
SCHEMBL7713338 0.76 PARP1 (0.42) PPARGPPARAPARP1ALDH1A1TP53
SCHEMBL7708144 0.76 PARP1 (0.42) PARP1ALDH1A1LMNATP53HPGD
SCHEMBL7713374 0.76 PARP1 (0.50) PARP1ALDH1A1LMNATP53MAPT
SCHEMBL7708475 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed